Posts

Posted on

FAF FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Reminds First American Financial Corp. Investors of Important Thursday Deadline in Securities Class Action Commenced by the Firm – FAF

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of First American Financial Corp. (NYSE: FAF) between February 17, 2017 and October 22, 2020, inclusive (the “Class Period”), of the important December 24, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for First American investors under the federal securities laws.

To join the First American class action, go to http://www.rosenlegal.com/cases-register-1662.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) First American failed to implement basic security standards to protect its customers’ sensitive personal information and data; (2) First American faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-egister-1662.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



Posted on

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Neovasc Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

PR Newswire

LOS ANGELES, Dec. 22, 2020 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neovasc Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between October 10, 2018 and October 27, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before January 5, 2021.           

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Neovasc’s COSIRA clinical study for its Reducer suffered from missing information in important areas. The study was not blinded, resulting in a control group less likely to participate further. This lack of blinding made the primary endpoint results difficult to interpret. The Company’s deficiencies in its study were likely to result in the FDA requesting additional clinical data. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Neovasc, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-action-notice-the-schall-law-firm-announces-the-filing-of-a-class-action-lawsuit-against-neovasc-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301197579.html

SOURCE The Schall Law Firm

Posted on

Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, expected to grow to $26.3 Billion by 2023

Achievement Highlighted by Important Process Improvements and Significantly Improved Economies of Scale

AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that it has completed the manufacturing scale-up of REQORSA™ immunogene therapy. The clinical-grade production is intended to supply the Company’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer, subject to passing final testing that is currently underway. The Company recently announced the successful manufacturing technology transfer to commercial Contract Development and Manufacturing Organizations (CDMOs) and the successful engineering run of REQORSA, that passed all testing specifications.

For the first time, REQORSA was manufactured in a scaled-up clinical production in accordance with the current Good Manufacturing Practices (cGMP) required by the U.S. Food and Drug Administration (FDA) in advance of commercial approval of a drug product. This product will supply the Company’s upcoming Acclaim-1 and Acclaim-2 clinical trials that combine REQORSA with Tagrisso® (marketed by AstraZeneca) and with Keytruda® (marketed by Merck & Co., Inc.), respectively, both of which are on track to be initiated in the first-half of 2021. This production includes process improvements that resulted in significantly higher yields and lower costs than prior manufacturing campaigns. Previously, REQORSA was manufactured at the major cancer research institution where it was invented.

“The scaled-up production of clinical-grade REQORSA is yet another significant manufacturing milestone for the Company,” said Michael Redman, Executive Vice President and Chief Operating Officer of Genprex. “Utilizing advanced processes, we were able to successfully improve our production yield multi-fold with significantly improved economies of scale. This production is intended to provide REQORSA for our upcoming Acclaim clinical trials. Furthermore, this achievement positions Genprex with the manufacturing capability for potential future commercialization in the rapidly growing lung cancer therapeutics market, which is projected to grow to $26.3 billion by 2023.”

Upon completion of testing and lot release, REQORSA will be transported to cold storage depots. These depots will facilitate shipments to the clinical trial sites following FDA clearance to commence the upcoming clinical trials. Unlike some biologicals that require shipment and storage at -80°C temperatures, REQORSA requires storage at only 2-8°C.

REQORSA is comprised of TUSC2 plasmid DNA (the active agent in REQORSA) encapsulated in non-viral nanoparticles that are administered intravenously and designed to target tumor cells.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining any FDA approvals of REQORSA and our other potential product candidates including whether we receive or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

[email protected]

Media Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) ext. #3

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Other Manufacturing Research Diabetes Clinical Trials Manufacturing Biotechnology Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Thinking about buying stock in Microvision, RMG Acquisition Corp, Marathon Patent Group, Kopin Corp, or Mohawk Group?

PR Newswire

NEW YORK, Dec. 22, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for MVIS, RMG, MARA, KOPN, and MWK.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-microvision-rmg-acquisition-corp-marathon-patent-group-kopin-corp-or-mohawk-group-301197550.html

SOURCE InvestorsObserver

Posted on

Thinking about trading options or stock in Apple, Peloton, FuelCell Energy, Editas Medicine, or Goldman Sachs?

PR Newswire

NEW YORK, Dec. 22, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for AAPL, PTON, FCEL, EDIT, and GS.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-apple-peloton-fuelcell-energy-editas-medicine-or-goldman-sachs-301197548.html

SOURCE InvestorsObserver

Posted on

Thinking about trading options or stock in General Electric, Plug Power, Crispr Therapeutics, Vista Outdoor, or Walt Disney?

PR Newswire

NEW YORK, Dec. 22, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for GE, PLUG, CRSP, VSTO, and DIS.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-general-electric-plug-power-crispr-therapeutics-vista-outdoor-or-walt-disney-301197553.html

SOURCE InvestorsObserver

Posted on

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Splunk Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

PR Newswire

LOS ANGELES, Dec. 22, 2020 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Splunk Inc. (“Splunk” or “the Company”) (NASDAQ: SPLK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between October 21, 2020 and December 2, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before February 2, 2021.           

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Splunk failed to close deals with large customers in the third quarter of fiscal 2021. The Company was not hitting the targets it had previously announced to the market. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about Splunk, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

 

Cision View original content:http://www.prnewswire.com/news-releases/investor-action-reminder-the-schall-law-firm-announces-the-filing-of-a-class-action-lawsuit-against-splunk-inc-and-encourages-investors-with-losses-in-excess-of-500-000-to-contact-the-firm-301197577.html

SOURCE The Schall Law Firm

Posted on

Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform

Proprietary Company design process facilitates rapid response in detecting mutation of a new coronavirus strain circulating in the UK

PR Newswire

SALT LAKE CITY, Dec. 22, 2020 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01. 

The new coronavirus strain comprises several mutations and may be more contagious than its predecessors. London and the southeast of Great Britain began Sunday morning at Level 4, which requires the effective closure of the affected areas, and further limits contact with others. Travel restrictions have also been put in place by countries concerned about exposure to the new strain of the virus.

Dwight Egan, CEO of Co-Diagnostics, commented “One of the most important advantages of our CoPrimer™ platform is its ability to reliably and accurately differentiate between similar genetic sequences, in order to reduce the likelihood of a false positive diagnosis. The multiplexing capabilities of our CoPrimer platform go hand-in-glove with the technology’s applications in detecting small genetic variations in a given gene. As we have demonstrated earlier on during this pandemic, our technology also facilitates rapid test development that we believe could help get testing solutions on the ground quickly as impactful mutations are identified.”

Co-Diagnostics also confirmed that the genetic mutations in the new variant are not believed to interfere with the performance of the Company’s existing line of COVID-19 diagnostics, and that any new test developed for this mutation would be a separate product, distinct from the Company’s other tests.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to rely on any forward-looking statements. Any forward-looking statement made by the Company in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-designs-test-to-detect-mutations-for-new-coronavirus-strain-using-coprimer-platform-301197387.html

SOURCE Co-Diagnostics

Posted on

CleanSpark Announces Additional 1,000 Unit ASIC Bitcoin Miner Order for January Delivery

Miners Ordered Since Acquisition to Increase Capacity by More Than 33%

PR Newswire

SALT LAKE CITY, Dec. 22, 2020 /PRNewswire/ — CleanSpark, Inc. (Nasdaq: CLSK), (“CleanSpark, or the Company”), an advanced software and controls technology solutions company, focused on solving modern energy challenges, is pleased to announce that it has secured an additional 1,000 ASICs (Application-specific integrated circuit) Bitcoin miners, slated for delivery and commissioning in the coming month. This order, when paired with the 500 ASICs announced last week and installation of the new S19s, is expected to increase the Company’s mining capacity by more than 100 PH/s to approximately 300 PH/s. 

CleanSpark’s Bitcoin Mining Capacity to Increase More Than 33%

“We are excited about demonstrating the efficiency of microgrid solutions on high-density energy operations. As we work towards the implementation of the facility power system upgrade, our focus is on maximizing the total Bitcoin output by immediately adding ASICs. In the Bitcoin mining industry, time is money, and due to the meteoric rise in price, ASIC miners are exceedingly difficult to procure. Many mining companies, both publicly traded and privately held, have stated plans to expand capacity in six to nine months, however we have focused on sourcing units for immediate deployment. As Bitcoin prices have continued to rise, and industry leaders such as Square, PayPal, MicroStrategy and others have made substantial investments in Bitcoin, we believe this strategy will provide exceptional returns for our shareholders,” stated Zachary Bradford, CleanSpark’s President and Chief Executive Officer. “This opportunity presented us a chance to deploy additional resources in furtherance of our strategy to utilize the available energy supply in the most efficient and profitable manner possible,” concluded Bradford.

Parties interested in learning more about CleanSpark products and services are encouraged to inquire by contacting the Company directly at [email protected] or visiting the Company’s website at www.cleanspark.com.

Investors are encouraged to contact the Company at [email protected], or visiting the Company’s website at https://ir.cleanspark.com/

CleanSpark periodically speaks at virtual conferences and events, if the event was recorded the recordings can be found on the events page at https://ir.cleanspark.com.

About CleanSpark:

CleanSpark, Inc., a Nevada corporation, is in the business of providing advanced software and controls technology solutions to solve modern energy challenges.  We have a suite of software solutions that provide end-to-end microgrid energy modeling, energy market communications and energy management solutions.  Our offerings consist of intelligent energy monitoring and controls, intelligent microgrid design software, middleware communications protocols for the energy industry, energy system engineering and software consulting services. 

About ATL Data Centers, LLC

ATL Data Centers LLC is a traditional data center operation located in the City of College Park, GA, just minutes from the Hartsfield-Jackson International Airport.  In addition to providing customers with rack space, power and equipment, ATL Data Centers LLC also offers several “Cloud Services” including, virtual services, virtual storage, and data backup services. 

ATL Data Centers also manages 23 mobile data centers, located on site, which can be used for a variety of purposes, including ASIC (application-specific integrated circuit) operations or other services requiring heavy power use.  The mobile data centers allow easy access to server maintenance, and each mobile data center has dedicated power and cooling.  ATL Data Centers LLC currently has 14 full time staff supporting the data center operation around-the-clock, 365 days per year.   The management team has a combined industry experience of more than 100 years. For more information, visit https://ATL-DATA.com

Forward-Looking Statements:

CleanSpark cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on CleanSpark’s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by CleanSpark that any of our plans will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including, without limitation: the successful integration of ATL into CleanSpark, the value of Bitcoin, the fitness of our energy software and solutions for this particular application or market, the expectations of future revenue growth may not be realized, ongoing demand for our software products and related services, the impact of global pandemics (including COVID-19) on the demand for our products and services; and other risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact – Investor Relations:
CleanSpark Inc.
Investor Relations
(801)-244-4405

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cleanspark-announces-additional-1-000-unit-asic-bitcoin-miner-order-for-january-delivery-301197386.html

SOURCE CleanSpark, Inc.

Posted on

Retailer in India Selects Bridgeline’s Celebros Search to Power Search and Merchandising on Their eCommerce Store

WOBURN, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a provider of cloud-based digital experience software, announced today a top manufacturer and retailer of decorative lighting in India has selected Celebros Search by Bridgeline as their site search solution for their online store.

The company is a tech-enabled market disruptor in decorative lighting and is India’s largest modern decorative lighting brand. The company was founded by Silicon Valley tech entrepreneurs with the goal of changing the highly disorganized decorative lighting market in India. They have seven luxury stores in Mumbai, Bangalore, and Hyderabad as well as their eCommerce store.

The company selected Bridgeline’s Celebros search to drive higher conversion rates on their online store and improve their customer’s overall experience. Celebros does this by improving search by delivering more relevant and accurate results and allowing their marketing team to easily merchandise, including their search results and category pages.

Bridgeline’s Search has intelligent, machine learning that understands user behavior and trends to provide the customer with accurate and relevant results and recommendations. Advanced Auto Complete offers predictive queries and recommendations that are based on real-time analytics in order to provide customers with highly accurate and relevant recommendations.

“We’re very excited to expand our footprint into India,” says Ari Kahn, CEO of Bridgeline Digital. “Our search software works with every major eCommerce platform and our intelligent, machine learning technology can help any company improve conversions, boost average order values and increase revenue,” Kahn added.

About Bridgeline Digital

Bridgeline Digital, The Digital Engagement Company, helps customers maximize the performance of their omni-channel digital experience from websites and intranets to online stores and campaigns. Bridgeline’s Unbound platform is a Digital Experience Platform (DXP) that deeply integrates Web Content Management, eCommerce, Marketing Automation, Site Search, Authenticated Portals, Social Media Management, Translation, Locator Pages and Web Analytics to help the goal of assisting marketers to help organizations deliver digital experiences that attract, engage, nurture and convert their customers across all channels and streamline business operations. OrchestraCMS is the only content and digital experience platform built 100% native on Salesforce. OrchestraCMS helps Salesforce create digital experiences for their customers and partners; combining content with business data, processes and applications across multiply channels and device including Salesforce Communities, social media, portals, intranets, websites, applications and services.  Celebros Search is a commerce oriented, site search product that provides for Natural Language Processing with artificial intelligence (AI) to present very relevant search results in seven languages. Headquartered in Woburn, MA., Bridgeline customers range from small- and medium-sized organizations to Fortune 1000 companies. To learn more, please visit www.bridgeline.com or call (800) 603-9936.

Contact:
Jeremy LaDuque
EVP of Marketing
Bridgeline Digital, Inc.
[email protected]